Biogen | BIIB - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 9.39B 4.16B 2026-03
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
ALKERMES USD 351.55M 37.02M 2026-03
Amgen USD 12.04B 2.91B 2026-03
Bayer EUR 6.67B 774M 2025-12
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Eli Lilly USD 5.28B 1.99B 2026-03
Esperion Therapeutics USD 156.16M 11.69M 2026-03
Gilead Sciences USD 7.56B 234M 2025-12
Incyte USD 4.02B 435.22M 2026-03
Merck USD 5.33B 9.24B 2026-03
Moderna USD 1.91B 687M 2026-03
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Novartis USD 6.88B 4.56B 2026-03
Pfizer USD 1.7B 561M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Puma Biotechnology USD 53.52M 1.14M 2025-09
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Sanofi EUR 5.54B 2.11B 2026-03
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
United Therapeutics USD 1.28B 277.4M 2026-03
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03